C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING

1 . A chemical compound having chemical formula (I):

wherein R 4 is a substituent containing:

(A) an ether moiety or a derivative thereof;

(B) a carbonic ester moiety or a derivative thereof;

(C) a carboxylic acid moiety or a derivative thereof;

(D) a polyether or a derivative thereof;

(E) a carbonothioate moiety or a derivative thereof; or

(F) a phosphate moiety or a derivative thereof;

wherein R 1 is a hydrogen atom or a moiety containing a carbonic ester or derivative thereof, or a ketone or ketone derivative; and

wherein R 3a and R 3b are each independently a hydrogen atom or an alkyl group.

2 . A chemical compound according to claim 1 , wherein R 4 is a substituent selected from:

(i) (A) an ether moiety or a derivative thereof;

(ii) (B) a carbonic ester moiety or a derivative thereof;

(iii) (D) a polyether or a derivative thereof; and

(iv) (F) a phosphate moiety or a derivative thereof.

3 . A chemical compound according to claim 24 , wherein in the compound having chemical formula (I) wherein R 4 is an ether moiety or derivative thereof, the compound having formula (I) has the chemical formula (XX):

wherein

R′ is an aryl group, a heteroaryl group, a heterocyclic group, an alkyl-aryl group, an alkyl-heterocyclic group, a silyl group, or an alkyl-heteroaryl group, wherein the aryl group, heteroaryl group, alkyl-aryl group, alkyl-heterocycle group, or alkyl-heteroaryl groups are substituted or unsubstituted, and wherein the optional substituents are a halo group, an amide group, an oxo group, or an alkyl group, wherein two or more alkyl groups optionally form an additional 5-7-membered ring.

4 . A chemical compound according to claim 2 , wherein in the compound having chemical formula (I) wherein R 4 is an ether moiety or derivative thereof, in the compound the ether moiety or derivative thereof can be an aryl ether group, a heteroaryl ether group, a heterocyclic ether group, an alkyl-aryl ether group, an alkyl-heterocyclic group, a silyl ether group, or an alkyl-heteroaryl group, wherein the aryl group, heteroaryl group, alkyl-aryl group, alkyl-heterocycle group, or alkyl-heteroaryl groups are substituted or unsubstituted, and wherein the optional substituents are a halo group, an amide group, an oxo group, or an alkyl group, wherein two or more alkyl groups optionally form an additional 5-7-membered ring.

5 .- 14 . (canceled)

15 . A chemical compound according to claim 2 , wherein in the compound having chemical formula (I) wherein R 4 is an ether moiety or derivative thereof, the compound is selected from the group consisting of A(I), A(II), A(III), A(IV), A(V), A(VI), A(VII), A(VIII), A(IX) and A(X):

16 . A chemical compound according to claim 2 , wherein in the compound having chemical formula (I) wherein R 4 is a carbonic ester moiety or derivative thereof, the compound having formula (I) has the chemical formula (XIV):

wherein

R 1 is a hydrogen atom or a carbonic ester moiety —O—C(═O)—O—(C 1 -C 6 )-alkyl, wherein the alkyl is optionally substituted with halo or C 6 -C 10 -aryl;

R′ is C 1 -C 10 -alkyl, wherein the C 1 -C 10 -alkyl group is optionally substituted with one or more of halo, C 6 -C 10 -aryl, C 3 -C 6 -cycloalkyl, or a polycyclic hydrocarbon.

17 - 18 . (canceled)

19 . A chemical compound according to claim 2 , wherein in the compound having chemical formula (I) wherein R 4 is a carbonic ester moiety or derivative thereof, the compound is selected from the group consisting of B(I), B(II), B(III), B(IV), B(V), and B(VI):

20 . A chemical compound according to claim 2 , wherein in the compound having formula (I) wherein R 4 is a polyether moiety or derivative thereof, the polyether moiety or derivative thereof includes a carboxylic acid moiety or derivative thereof.

21 . A chemical compound according to claim 2 , wherein the polyether moiety or derivative thereof is selected from the group of compounds consisting of D(I), D(II), D(III), D(IV), D(V), D(VI), D(VII), D(VIII), D(IX), D(X), D(XI), D(XII), D(XIII), D(XIV), D(XV), D(XVI), D(XVII), D(XVIII), and D(XIX):

22 .- 34 . (canceled)

35 . A chemical compound according to claim 2 , wherein in the compound having chemical formula (I) wherein R 4 is a phosphate moiety or derivative thereof, the compound having formula (I) has chemical formula (XVI):

wherein,

X is O or NH;

each R p is independently or simultaneously alkyl, aryl, or each R p is joined together to form an optionally substituted 4-7-membered heterocyclic ring.

36 . A chemical compound according to claim 2 , wherein in the compound having chemical formula (I) wherein R 4 is a phosphate moiety or derivative thereof, the compound is selected from the group consisting of F(I), F(II), F(III), F(IV), F(V), F(VI), F(VII), F(VIII), F(IX), F(X), F(XI), F(XII), F(XIII), F(XIV), and F(XV):

37 - 42 . (canceled)

43 . A chemical compound according to claim 2 , wherein R 1 is a carbonic ester having chemical formula (V) or (XIII):

44 .- 45 . (canceled)

46 . A chemical compound according to claim 1 , wherein R 4 is a substituent selected from:

(i) (A) an ether moiety or a derivative thereof;

(ii) (B) a carbonic ester moiety or a derivative thereof;

(iii) (D) a polyether or a derivative thereof; and

(iv) (F) a phosphate moiety or a derivative thereof,

wherein (NR 3a R 3b ) has the formula (N + HR 3a R 3b Z), wherein Z is a counter-balancing anion, and wherein compound (I) is a salt.

47 . A chemical compound according to claim 13 , wherein Z is a mono-valent counter-balancing ion (Z − ), a di-valent counter-balancing ion (Z 2− ), or a tri-valent counter-balancing ion (Z 3− ).

48 . A chemical compound according to claim 13 , wherein Z is a mono-valent counter-balancing anion (Z − ) selected from a halide ion (Cl − , Br − , F − , I − ), a nitrate ion (NO 3 − ), a benzoate ion (phenyl-COO − ), a succinate ion (HOOC—(CH 2 ) 2 —COO − ), a fumarate ion (trans-HOOC—(CH═CH)—COO − ), a tartarate ion (HOOC—(CHOH) 2 —COO − ), a malate ion (HOOC—CH 2 —CHOH—COO − ), a maleate ion (cis-HOOC—(CH═CH)—COO − ), a dibenzoyl tartarate ion (HOOC—(CHOBz) 2 -COO − ), a ditoluoyl tartarate ion (HOOC—(CHOCOTol) 2 -COO − ), a malonate ion (HOOC—CH 2 —COO − ), a dihydrogen phosphate ion (H 2 PO 4 − ), and an acetate ion (CH 3 —COO − ), wherein the salt compound has the formula (I a ):

49 . A chemical compound according to claim 13 , wherein Z is a di-valent counter-balancing anion (Z 2− ) selected from a sulfate ion (SO 4 2− ), a hydrogen phosphate ion (HPO 4 2− ), a succinate dianion ( − OOC—(CH 2 ) 2 —COO − ), a fumarate dianion (trans- − OOC—(CH═CH)—COO − ), a tartarate dianion ( − OOC—(CHOH) 2 —COO − ), a malate dianion ( − OOC—CH 2 —CHOH—COO − ), a maleate dianion (cis- − OOC—(CH═CH)—COO − ), a dibenzoyl tartarate dianion ( − OOC—(CHOBz) 2 -COO − ), a ditoluoyl tartarate dianion ( − OOC—(CHOCOTol) 2 -COO − ), and a malonate dianion (—OOC—CH 2 —COO − ), wherein the salt compound has the formula (I b ):

50 . A chemical compound according to claim 13 , wherein Z is a tri-valent counter-balancing anion (Z 3− ) selected from a phosphate ion (PO 4 3− ) and a citrate ion ( − OOC—CH 2 —C(OH)(COO − )—CH 2 —COO − , and the salt compound has the formula (I c ):

51 . A pharmaceutical or recreational drug formulation comprising an effective amount of a chemical compound having a formula (I) according to claim 2 , together with a pharmaceutically acceptable excipient, diluent, or carrier.

52 .- 57 . (canceled)

58 . A method for treating a psychiatric disorder, the method comprising administering to a subject in need thereof a pharmaceutical formulation according to claim 18 , wherein the pharmaceutical formulation is administered in an effective amount to treat the psychiatric disorder in the subject.

59 .- 67 . (canceled)

68 . A method for modulating (i) a receptor selected from 5-HT 1A receptor, a 5-HT 2A receptor, a 5-HT 1B receptor, a 5-HT 2B receptor, a 5-HT 3A receptor, an ADRA1A receptor, an ADRA2A receptor, a CHRM1 receptor, a CHRM2 receptor, a CNR1 receptor, a DRD1 receptor, a DRD2S receptor, or an OPRD1 receptor; (ii) an enzyme, the enzyme being MOA-1; or (iii) a transmembrane transport protein selected from a dopamine active transporter (DAT), a norephedrine transporter (NET) or a serotonin transporter (SERT) transmembrane transport protein, the method comprising contacting (i) the 5-HT 1A receptor, the 5-HT 2A receptor, the 5-HT 1B receptor, the 5-HT 2B receptor, the 5-HT 3A receptor, the ADRA1A receptor, the ADRA2A receptor, the CHRM1 receptor, the CHRM2 receptor, the CNR1 receptor, the DRD1 receptor, the DRD2S receptor, or the OPRD1 receptor; (ii) MOA-1; or (iii) the dopamine active transporter (DAT), the norephedrine transporter (NET), or the serotonin transporter (SERT) transmembrane transport protein with a chemical compound having a formula (I) according to claim 2 :

wherein R 4 is a substituent selected from:

(A) an ether moiety or derivative thereof;

(B) a carbonic ester moiety or derivative thereof;

(C) a carboxylic acid moiety or derivative thereof;

(D) a polyether moiety or derivative thereof;

(E) a carbonothioate moiety or derivative thereof; and

(F) a phosphate moiety or derivative thereof,

wherein R 1 is a hydrogen atom or a moiety containing a carbonic ester or derivative thereof, or a ketone or ketone derivative; and

wherein R 3a and R 3b are each independently a hydrogen atom or an alkyl group, under reaction conditions sufficient to modulate (i) the 5-HT 1A receptor, the 5-HT 2A receptor, the 5-HT 1B receptor, the 5-HT 2B receptor, the 5-HT 3A receptor, the ADRA1A receptor, the ADRA2A receptor, the CHRM1 receptor, the CHRM2 receptor, the CNR1 receptor, the DRD1 receptor, the DRD2S receptor, or the OPRD1 receptor; (ii) MOA-1; or (iii) the dopamine active transporter (DAT), the norephedrine transporter (NET), or the serotonin transporter (SERT) transmembrane transport protein.

69 .- 91 . (canceled)